Journal: JMA Journal

Article Title: Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis

doi: 10.31662/jmaj.2023-0171

Figure Lengend Snippet: Population Characteristics of the Included Studies.

Article Snippet: Terpos et al., 2021, Greece, Prospective cohort , Dose 1: , CLL, NHL, HL , Mean ± SD: 64.6 ± 14.3, 50% , BNT162b2 , 21D , First Dose and Second Dose , Mean ± SD: 69.8 ± 12.5, 44.9% , First Dose: 152 , , , GenScript (≥30% = positive, ≥30% = clinically relevant) , 6.

Techniques: Comparison, Inhibition, Neutralization

Journal: Clinical Lymphoma, Myeloma & Leukemia

Article Title: COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis

doi: 10.1016/j.clml.2022.03.012

Figure Lengend Snippet: Characteristics of Studies Included in the Meta-Analysis

Article Snippet: Achiron A , 79 , Israel , MS , 44 , 10 , 53.2 , healthy , 47 , 46 , 54.3 , BNT162b2 , 1 mo , spike (S1) , EUROIMMUN (ELISA) , index value 1.1 , 9.

Techniques: Enzyme-linked Immunosorbent Assay, Ii Assay, Chemiluminescence Immunoassay, Multiplex Assay, Luminex, Tandem Mass Spectroscopy, Transplantation Assay

Journal: medRxiv

Article Title: Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years

doi: 10.1101/2022.10.28.22281532

Figure Lengend Snippet: Study start date was the earliest EUA date for the BNT162b2 vaccination for each age group: Age 5-11: 10/29/2021 Age 12-15: 5/10/2021 Age 16-17: 12/11/2020 Data cuts: CVS Health data through 5/31/2022, HealthCore data through 5/6/2022, and Optum data through 6/25/2022

Article Snippet: Approximately 5.9 million BNT162b2 COVID-19 vaccine doses were administered to over 3 million commercial health plan enrollees aged 5-17 years across the three databases; 1,999,550 doses were observed in 1,000,895 enrollees in CVS Health; 2,033,212 doses in 1,078,712 enrollees in HealthCore; and 1,869,063 doses in 937,745 enrollees in Optum database ( ).

Techniques:

Journal: eClinicalMedicine

Article Title: Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review

doi: 10.1016/j.eclinm.2022.101624

Figure Lengend Snippet: Summary of results for ‘vaccine - infection - long COVID’ studies.

Article Snippet: Taquet et al. 2022 United States of America , Retrospective Cohort January 1, 2021 to August 31, 2021 , n = 18,958 Female = 11,437 Hospitalized = No Data , Mean (SD), at infection: Vaccinated: 56.5 (18.0) years Unvaccinated: 57.6 (20.6) years , 9479 participants vaccinated with COVID-19 vaccine , 9479 participants unvaccinated with COVID-19 vaccine but with influenza vaccine at any time , TriNetX Analytics (Federated Network of Linked Electronic Health Records) , Abdominal symptoms Abnormal breathing Anxiety/Depression Chest/Throat Pain Cognitive symptoms Fatigue Headache Myalgia Other pain , Product: BNT162b2, mRNA 1273 Ad26.COV2.S, unspecified subtype Dose: 1-2 Follow-up: within 6 months , Fatigue (HR 0.89, 95% CI 0.81–0.97) Myalgia (HR 0.78, 95% CI 0.67-0.91) Pain (HR 0.90, 95% CI 0.81-0.99) Abnormal breathing (HR 0.89, 95% CI 0.81–0.98) Cognitive symptoms (HR 0.87, 95% CI 0.76–0.99) HR for other symptoms were not reported.

Techniques: Infection, Control, Coagulation

Journal: eClinicalMedicine

Article Title: Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review

doi: 10.1016/j.eclinm.2022.101624

Figure Lengend Snippet: Summary of results for ‘infection - long COVID - vaccine’ studies.

Article Snippet: Taquet et al. 2022 United States of America , Retrospective Cohort January 1, 2021 to August 31, 2021 , n = 18,958 Female = 11,437 Hospitalized = No Data , Mean (SD), at infection: Vaccinated: 56.5 (18.0) years Unvaccinated: 57.6 (20.6) years , 9479 participants vaccinated with COVID-19 vaccine , 9479 participants unvaccinated with COVID-19 vaccine but with influenza vaccine at any time , TriNetX Analytics (Federated Network of Linked Electronic Health Records) , Abdominal symptoms Abnormal breathing Anxiety/Depression Chest/Throat Pain Cognitive symptoms Fatigue Headache Myalgia Other pain , Product: BNT162b2, mRNA 1273 Ad26.COV2.S, unspecified subtype Dose: 1-2 Follow-up: within 6 months , Fatigue (HR 0.89, 95% CI 0.81–0.97) Myalgia (HR 0.78, 95% CI 0.67-0.91) Pain (HR 0.90, 95% CI 0.81-0.99) Abnormal breathing (HR 0.89, 95% CI 0.81–0.98) Cognitive symptoms (HR 0.87, 95% CI 0.76–0.99) HR for other symptoms were not reported.

Techniques: Infection, Control, Plasmid Preparation, Concentration Assay, Significance Assay, Modification